Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus

Abstract

Get full access to this article

View all access options for this article.

References

Mestanza-Peralta M. , Ariza-Ariza R. , Cardiel MH , Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997; 24: 867-870.

Miller MH , Urowitz MB , Gladman DD The significance of thrombocytopenia in systemic lupus erythematosus . Arthritis Rheum 1983; 26: 1181-1186.

Gunnarsson I. , Sundelin B. , Jonsdottir T. , Jacobson SH , Henriksson EW , van Vollenhoven RF Histopathologic and clinical outcome of Rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272.

Perrotta S. , Locatelli F. , La Manna A. , Cennamo L. , De Stefano P. , Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 465-467.

Lindholm C. , Borjesson-Asp K. , Zendjanchi K. , Sundqvist AC , Tarkowski A. , Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35: 826-833.

Lehembre S. , Macario-Barrel A. , Musette P. , Carvalho P. , Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 2006; 133: 53-55.